Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer
Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalitie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/10/11/413 |
| _version_ | 1797716415619268608 |
|---|---|
| author | Pei-Yi Wu Yueh-Chien Lin Yuan-Li Huang Wei-Min Chen Chien-Chin Chen Hsinyu Lee |
| author_facet | Pei-Yi Wu Yueh-Chien Lin Yuan-Li Huang Wei-Min Chen Chien-Chin Chen Hsinyu Lee |
| author_sort | Pei-Yi Wu |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA⁻VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa. |
| first_indexed | 2024-03-12T08:21:07Z |
| format | Article |
| id | doaj.art-d01c259d5b45406bb297f25fcc4b4d5c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T08:21:07Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d01c259d5b45406bb297f25fcc4b4d5c2023-09-02T18:31:53ZengMDPI AGCancers2072-66942018-10-01101141310.3390/cancers10110413cancers10110413Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate CancerPei-Yi Wu0Yueh-Chien Lin1Yuan-Li Huang2Wei-Min Chen3Chien-Chin Chen4Hsinyu Lee5Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, TaiwanDepartment of Life Sciences, National Taiwan University, Taipei 10617, TaiwanDepartment of Biotechnology, Asia University, Taichung 41354, TaiwanDepartment of Life Sciences, National Taiwan University, Taipei 10617, TaiwanDepartment of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, TaiwanDepartment of Life Sciences, National Taiwan University, Taipei 10617, TaiwanProstate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA⁻VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa.https://www.mdpi.com/2072-6694/10/11/413LPALPA receptorprostate cancerVEGF-Clymphangiogenesis |
| spellingShingle | Pei-Yi Wu Yueh-Chien Lin Yuan-Li Huang Wei-Min Chen Chien-Chin Chen Hsinyu Lee Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer Cancers LPA LPA receptor prostate cancer VEGF-C lymphangiogenesis |
| title | Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer |
| title_full | Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer |
| title_fullStr | Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer |
| title_full_unstemmed | Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer |
| title_short | Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer |
| title_sort | mechanisms of lysophosphatidic acid mediated lymphangiogenesis in prostate cancer |
| topic | LPA LPA receptor prostate cancer VEGF-C lymphangiogenesis |
| url | https://www.mdpi.com/2072-6694/10/11/413 |
| work_keys_str_mv | AT peiyiwu mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer AT yuehchienlin mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer AT yuanlihuang mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer AT weiminchen mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer AT chienchinchen mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer AT hsinyulee mechanismsoflysophosphatidicacidmediatedlymphangiogenesisinprostatecancer |